A phase I trial for advanced esophageal squamous cell carcinoma in patients with HLA-A*2402 demonstrated that a combination of LY6K and TTK with CpG-7909 elicited potent LY6K-specific T cell responses. Here, HLA-A is linked to esophageal squamous cell carcinoma.